Michael Martin Breen serves as Executive at GT Biopharma, Inc., where they oversee executive responsibilities. Since joining the company, Michael Martin Breen has executed 8 insider transactions totaling $125.8K, demonstrating a bullish approach to their equity position. Their most recent transaction on Aug 11, 2023 involved receiving (via award) 200,000 shares valued at $58.0K.
Michael Martin Breen currently holds 856,218 shares of GT Biopharma, Inc. (GTBP), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Michael Martin Breen has been a net buyer of GTBP stock. They have purchased $125.8K and sold $0 worth of shares.
Michael Martin Breen's most recent insider trade was on Aug 11, 2023, when they sold 200,000 shares at $0.29 per share.
Get notified when new Form 4 filings are submitted
| $0.18 |
| Discretionary |
| May 3, 2023 | CRKR | $100.8K | Purchase | 916,112 | $0.11 | Discretionary |
| Apr 11, 2023 | GTBP | $25.0K | Purchase | 50,000 | $0.50 | Discretionary |
| Jul 15, 2022 | GTBP | $0 | Award | 278,058 | $N/A | Discretionary |
| Feb 25, 2021 | GTBP | $136.8K | Conversion | 40,243 | $3.40 | Discretionary |
| Feb 25, 2021 | GTBP | $33.5K | Conversion | 9,859 | $3.40 | Discretionary |
| Feb 16, 2021 | GTBP | $0 | Award | 278,058 | $N/A | Discretionary |